Published in

Massachusetts Medical Society, New England Journal of Medicine, 22(373), p. 2117-2128

DOI: 10.1056/nejmoa1504720

Links

Tools

Export citation

Search in Google Scholar

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Journal article published in 2015 by M. d’Emden, T. vab Bemmel, A. de Jong, J. van Soest, G. Zwiers, W. Zmuda, F. del Cañizo, L. de Teresa, S. Zotov, D. Aizenberg, M. Ulla, J. Waitman, L. De Loredo, J. Farías, H. Fideleff and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Orange circle
Published version: archiving restricted
Data provided by SHERPA/RoMEO

Abstract

The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.